Breakpoint Therapeutics develops anti-cancer drugs by modulating DNA damage responses to enhance the efficacy of existing treatments. This approach targets the inherent weaknesses in cancer cell repair mechanisms, aiming to improve patient outcomes and reduce treatment resistance.
Funding
$33.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many cancer cells develop resistance to existing treatments by enhancing their DNA damage repair mechanisms. This resistance limits the effectiveness of therapies and contributes to poor patient outcomes.
Solution
Breakpoint Therapeutics is developing a new class of anti-cancer drugs that modulate DNA damage responses (DDR) in cancer cells. By targeting the specific pathways cancer cells use to repair damaged DNA, Breakpoint's approach aims to disrupt their ability to overcome the effects of chemotherapy and radiation. This modulation enhances the efficacy of existing treatments, potentially leading to improved patient outcomes and reduced treatment resistance. The company's focus is on exploiting the inherent vulnerabilities in cancer cell repair mechanisms to create more effective and durable therapies.
Target Audience
Breakpoint Therapeutics' primary target audience includes pharmaceutical companies, oncologists, and cancer researchers focused on developing and improving cancer treatment regimens.
Features
- Development of small molecule inhibitors targeting key DNA damage response proteins.
- Focus on modulating specific DDR pathways to selectively sensitize cancer cells to treatment.
- Preclinical studies demonstrating enhanced efficacy of existing cancer therapies when combined with Breakpoint's DDR modulators.